Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

被引：20
|
作者：
Andre, Thierry
Lonardi, Sara
Wong, Ka Yeung Mark
Morse, Michael
McDermott, Raymond S.
Hill, Andrew Graham
Hendlisz, Alain
Lenz, Heinz-Josef
Leach, Joseph W.
Moss, Rebecca Anne
Cao, Z. Alexander
Ledeine, Jean-Marie
Chan, Emily
Kopetz, Scott
Michael, J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3531
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [2] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [3] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    [J]. ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [4] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Andre, T.
    Van Cutsem, E.
    Elez, E.
    Bennouna, J.
    de la Fouchardiere, C.
    Yoshino, T.
    Jensen, L.
    Mendez, G.
    Li, J.
    Goekkurt, E.
    Abdullaev, S.
    Chen, T.
    Lei, M.
    Lonardi, S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
  • [5] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
    Abdullaev, Sandzhar
    Andre, Thierry
    Lei, Ming
    Lenz, Heinz-Josef
    Novotny, James
    Paulson, Andrew Scott
    Tejpar, Sabine
    Yamazaki, Kentaro
    Ledeine, Jean-Marie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142
    Andre, T.
    Overman, M.
    Lonardi, S.
    Aglietta, M.
    McDermott, R.
    Wong, K. Y. M.
    Morse, M.
    Hendlisz, A.
    Moss, R. A.
    Ledeine, J-M.
    Tang, H.
    Cao, Z. A.
    Kopetz, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [8] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
    Lenz, Heinz-Josef
    Overman, Michael J.
    Van Cutsem, Eric
    Limon, Maria Luisa
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    McCraith, Stephen
    Wang, Rui
    Lei, Ming
    Yao, Jin
    Jin, Lixian
    Lonardi, Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 97 - 97
  • [10] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
    Lenz, Heinz-Josef
    Overman, Michael J.
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Mark Ka
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    McCraith, Stephen M.
    Wang, Abigail
    Lei, Ming
    Yao, Jin
    Jin, Lixian
    Lonardi, Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345